Please assess the completion status of the following clinical trial:

Trial Title: The Effects of an Antioxidant Formulation on Ocular Blood Flow

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 30 years or older.~* Confirmed diagnosis of open angle glaucoma by glaucoma specialist in the study eye, as evidenced from criteria representative of glaucomatous optic nerve damage such as specific optic disc or retinal nerve fiber layer structural abnormalities and/or visual field abnormalities.~* Best corrected visual acuity at 20/60 or better in study eye.~* Willingness to avoid caffeine and smoking for 12 hours before and during the study visits.~Exclusion Criteria:~* History of acute angle-closure or a narrow, occluding of anterior chamber angle by gonioscopy.~* History of chronic or recurrent inflammatory eye diseases or signs of intraocular trauma and/or unreliable applanation tonometry.~* Severe, unstable or uncontrolled cardiovascular, renal or pulmonary disease~* History of/or current renal or hepatic impairment.~* History of/or current bronchial asthma, severe chronic obstructive pulmonary disease, sinus bradycardia, second or third degree atrioventricular block, or cardiogenic shock.~* Recent surgery or surgery planned near study timeline~* History of bleeding disorder~* Use of blood thinning medications~* Use of specified dietary supplements for three weeks prior to study entry and throughout study period.

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- supplement w/ antioxidants then placebo (Type: EXPERIMENTAL): dietary supplement with antioxidants, followed by placebo supplement
- placebo then supplement w/ antioxidants (Type: EXPERIMENTAL): placebo supplement, followed by dietary supplement with antioxidants

Based on this trial design, predict the completion outcome and termination type (if applicable).